| Date | Title | Description |
| 03.09.2026 | Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM) | Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dime... |
| 24.08.2026 | Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease | NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clin... |
| 21.04.2026 | Pulnovo Medical scores $100M in finance round led by Medtronic | Pulnovo Medical, a Chinese medtech focused on therapies that target pulmonary hypertension and heart failure, hauled in $100 million in an oversubscribed finance round led by Medtronic.
Funds from the round will support ongoing clinical dev... |
| 20.04.2026 | Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round | NEW YORK, April 20, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic finan... |
| 03.03.2025 | Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing | SHANGHAI, March 3, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has announced the closing of nearly $100 million Series C financing. This roun... |
| 02.01.2024 | Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval | SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained Humanitarian U... |
| 07.09.2022 | Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH | SHANGHAI, Sept. 7, 2022 /PRNewswire/ -- A globally recognized OTM innovative platform Pulnovo Medical Limited's proprietary Pulmonary Artery Denervation (PADN) technology has been included in the 2022 ESC/ERS Guidelines for the Diagnosis an... |
| - | Pulnovo Medical | “Pa Mother medical” |
